Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry

Abstract

From 2000 to 2005, significantly improved treatment responses to TNF inhibitors were seen in clinical practice despite decreasing baseline disease activity levels. This lends support to the less stringent prescription practice towards treating patients with lower disease activity that has been observed in several countries.

„Treat-To-Target“ aus der Sicht der niedergelassenen Rheumatologie

“…Hierfür eignen sich am besten die publizierten Daten aus der Kerndokumentation sowie aus RAB-BIT, dem deutschen Biologikaregister mit integrierter DMARD-Kontrollgruppe. [4].…”

Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry

“…The mandatory reporting of biological treatment to the database makes coverage and completeness of data high 27 28. The registry currently includes up to 8 years of follow-up.…”

Biologics registers in RA: methodological aspects, current role and future applications

“…7 The study of register data over time has provided insights into secular changes in the use of biologics, demonstrating earlier use following fewer csDMARDs in patients with lesser amounts of disability and corticosteroid exposure. 8,9 Biologic Treatment Effectiveness …”